Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04184622 · ClinicalTrials.gov registry record · Phase 3
A Study of Tirzepatide (LY3298176) in Participants With Obesity or Overweight
A Phase 3 study, sponsored by Eli Lilly and Company.
- Completed
- Registry status
- Phase 3
- Development phase
- 2,539
- Enrollment target
NCT04184622: Completed Phase 3 study, sponsored by Eli Lilly and Company.
NCT04184622 is a Phase 3 study that has completed, run by Eli Lilly and Company. The registered enrollment target is 2,539 participants, above the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (229% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04184622, a Phase 3 study, has completed, sponsored by Eli Lilly and Company.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 2,539 participants
- Enrollment target
Study Summary
This is a study of tirzepatide in participants with overweight and obesity. The main purpose is to learn more about how tirzepatide affects body weight. The study has two phases: A main phase and an extension phase. The main phase of the study will last 72 weeks. Participants with prediabetes will continue in the extension for another 2 years.
Primary Outcome
Least Squares (LS) Mean was calculated using mixed-model repeated measures (MMRM) with baseline, analysis country, sex, prediabetes status at randomization, treatment, time, treatment\*time (Type III sum of squares) in the model.
Interventions
- DRUG Placebo
- DRUG Tirzepatide
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 2,539 participants |
| Start Date | 2019-12-04 |
| Est. Completion | 2024-07-06 |
| Phase | Phase 3 |
What the finished NCT04184622 record still lists
NCT04184622 is an interventional study that assigns participants to a tested intervention. Its 2,539 participants enrollment target places it among the larger protocols in the corpus, above the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (229% higher).
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT04184622 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT04184622 about?
NCT04184622 is a clinical study titled "A Study of Tirzepatide (LY3298176) in Participants With Obesity or Overweight". This is a study of tirzepatide in participants with overweight and obesity. The main purpose is to learn more about how tirzepatide affects body weight. The study has two phases: A main phase and an extension phase. The main phase of the study will last 72 weeks. Participants with prediabetes will c...
What is the current status of trial NCT04184622?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 2,539 participants. The study started on 2019-12-04. Estimated completion is 2024-07-06.
What interventions are being tested in trial NCT04184622?
The interventions under investigation include: Placebo (DRUG), Tirzepatide (DRUG).
Who is sponsoring clinical trial NCT04184622?
This trial is sponsored by Eli Lilly and Company, which has 1,341 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT04184622's enrollment target sits among peer trials
2,539 87th of 2000 higher than 1,914 of 2,000 other Phase 3 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 3 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT05931276 · 2,540 participants · Phase 3
CSP #2026 - Beta Blocker Dialyzability on Cardiovascular Outcomes
- NCT00018057 · 2,530 participants · Phase 2
Study of Neuro-Cognitive Correlates of Pediatric Anxiety Disorders
- NCT04142177 · 2,529 participants · NA
Sequential and Comparative Evaluation of Pain Treatment Effectiveness Response
- NCT06018285 · 2,572 participants · NA
Stepped Approach to Reducing Risk of Suicide in Primary Care
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI